Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bioxcel Therapeutics Inc (BTAI)

Bioxcel Therapeutics Inc (BTAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,706
  • Shares Outstanding, K 21,869
  • Annual Sales, $ 2,270 K
  • Annual Income, $ -59,600 K
  • EBIT $ -51 M
  • EBITDA $ -50 M
  • 60-Month Beta 0.21
  • Price/Sales 18.43
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 97.71%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 675.37% on 01/24/25
  • IV Low 0.00% on 12/05/25
  • Expected Move (DTE 42) 0.04 (2.31%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 10
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 9,316
  • Open Int (30-Day) 9,310
  • Expected Range 1.80 to 1.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.82
  • Number of Estimates 1
  • High Estimate -0.82
  • Low Estimate -0.82
  • Prior Year -3.57
  • Growth Rate Est. (year over year) +77.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.53 +35.29%
on 11/14/25
2.33 -11.14%
on 11/28/25
+0.21 (+11.29%)
since 11/05/25
3-Month
1.53 +35.29%
on 11/14/25
4.29 -51.75%
on 09/08/25
-1.72 (-45.38%)
since 09/05/25
52-Week
1.17 +76.92%
on 05/30/25
9.26 -77.64%
on 01/06/25
-4.04 (-66.13%)
since 12/05/24

Most Recent Stories

More News
Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions

Event Sponsored by BioXcel Therapeutics Set for 10 a.m. EST on Monday, Dec. 8 Topics Covered by Drs. Leslie Citrome, Marc Milano, and Leon Ravin to Include Opportunities and Advantages of Self-Administered...

BTAI : 2.07 (-0.96%)
BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease

NEW HAVEN, Conn., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience,...

BTAI : 2.07 (-0.96%)
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

BTAI : 2.07 (-0.96%)
H.C. Wainwright Keeps Their Buy Rating on Bioxcel Therapeutics (BTAI)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Bioxcel Therapeutics, with a price target of $10.00. The company’s shares closed yesterday at $2.68.Elevate Your...

BTAI : 2.07 (-0.96%)
BioXcel Announces Positive SERENITY At Home Study Results

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update...

BTAI : 2.07 (-0.96%)
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes

NEW HAVEN, Conn., Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience,...

BTAI : 2.07 (-0.96%)
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation

NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) , a biopharmaceutical company pioneering the use of artificial intelligence to develop transformative medicines...

BTAI : 2.07 (-0.96%)
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements

NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today...

BTAI : 2.07 (-0.96%)
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p

BTAI : 2.07 (-0.96%)
BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

NEW HAVEN, Conn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience,...

BTAI : 2.07 (-0.96%)

Business Summary

BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film...

See More

Key Turning Points

3rd Resistance Point 2.26
2nd Resistance Point 2.21
1st Resistance Point 2.14
Last Price 2.07
1st Support Level 2.02
2nd Support Level 1.98
3rd Support Level 1.91

See More

52-Week High 9.26
Fibonacci 61.8% 6.17
Fibonacci 50% 5.21
Fibonacci 38.2% 4.26
Last Price 2.07
52-Week Low 1.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar